Literature DB >> 3034028

Clinical pharmacology of ramipril.

S G Ball, J I Robertson.   

Abstract

Ramipril is a long-acting non-sulphydryl converting enzyme inhibitor that requires cleavage of its ester group to form the active diacid metabolite, ramiprilat. Renal excretion largely determines the drug's duration of action and the dosage should be reduced in patients with renal impairment. Oral ramipril given daily at dosages of 5 mg or more can control blood pressure over a 24-hour period; lower doses may be effective in patients with heart failure inadequately controlled by diuretics alone. No serious idiosyncratic adverse reactions have been reported. Ramipril is one of the most potent long-acting converting enzyme inhibitors developed; it is effective given once daily in the treatment of all grades of hypertension and of heart failure.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3034028     DOI: 10.1016/0002-9149(87)90048-8

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

Review 1.  Newer ACE inhibitors. A look at the future.

Authors:  A Salvetti
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

Review 2.  Ramipril. A review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders.

Authors:  P A Todd; P Benfield
Journal:  Drugs       Date:  1990-01       Impact factor: 9.546

3.  Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE).

Authors:  D W Cushman; F L Wang; W C Fung; G J Grover; C M Harvey; R J Scalese; S L Mitch; J M DeForrest
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

4.  Acute haemodynamic effects and pharmacokinetics of ramipril in patients with heart failure. A placebo controlled three-dose study.

Authors:  B Beermann; O Nyquist; C Höglund; K A Jacobsson; U Näslund; M Jensen-Urstad
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 5.  Clinical pharmacokinetics of vasodilators. Part I.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

Review 6.  Ramipril. An updated review of its therapeutic use in essential hypertension and heart failure.

Authors:  J E Frampton; D H Peters
Journal:  Drugs       Date:  1995-03       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.